Cargando…

Low-Molecular-Weight Heparin or Dual Antiplatelet Therapy Is More Effective Than Aspirin Alone in Preventing Early Neurological Deterioration and Improving the 6-Month Outcome in Ischemic Stroke Patients

BACKGROUND AND PURPOSE: Dual antiplatelet therapy (DAT) with clopidogrel and aspirin has been shown to confer greater protection against early neurological deterioration (END) and early recurrent ischemic stroke (ERIS) than aspirin alone in patients who have experienced an acute ischemic stroke. How...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Xingyang, Chi, Wanzhang, Wang, Chun, Zhang, Biao, Lin, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Neurological Association 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302180/
https://www.ncbi.nlm.nih.gov/pubmed/25628738
http://dx.doi.org/10.3988/jcn.2015.11.1.57
_version_ 1782353754329186304
author Yi, Xingyang
Chi, Wanzhang
Wang, Chun
Zhang, Biao
Lin, Jing
author_facet Yi, Xingyang
Chi, Wanzhang
Wang, Chun
Zhang, Biao
Lin, Jing
author_sort Yi, Xingyang
collection PubMed
description BACKGROUND AND PURPOSE: Dual antiplatelet therapy (DAT) with clopidogrel and aspirin has been shown to confer greater protection against early neurological deterioration (END) and early recurrent ischemic stroke (ERIS) than aspirin alone in patients who have experienced an acute ischemic stroke. However, few studies have compared the effects of anticoagulation therapy with low-molecular-weight heparin (LMWH), DAT, and aspirin. METHODS: Patients with acute ischemic stroke (n=1,467) were randomized to therapy groups receiving aspirin (200 mg daily for 14 days, followed by 100 mg daily for 6 months), DAT (200 mg of aspirin and 75 mg of clopidogrel daily for 14 days, then 100 mg of aspirin daily for 6 months), or LMWH (4,000 antifactor Xa IU of enoxaparin in 0.4 mL subcutaneously twice daily for 14 days, followed by 100 mg of aspirin daily for 6 months). The effects of these treatment strategies on the incidence of END, ERIS, and deep-vein thrombosis (DVT) were observed for 10-14 days after treatment, and their impacts on a good outcome were evaluated at 6 months. RESULTS: The DAT and LMWH were associated with a more significant reduction of END and ERIS within 14 days compared with aspirin-alone therapy. In addition, LMWH was associated with a significantly lower incidence of DVT within 14 days. At 6 months, DAT or LMWH improved the outcome among patients aged >70 years and those with symptomatic stenosis in the posterior circulation or basilar artery compared with aspirin. CONCLUSIONS: LMWH or DAT may be more effective than aspirin alone for reducing the incidence of END and ERIS within 14 days, and is associated with improved outcomes in elderly patients and those with stenosis in the posterior circulation or basilar artery at 6 months poststroke.
format Online
Article
Text
id pubmed-4302180
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Korean Neurological Association
record_format MEDLINE/PubMed
spelling pubmed-43021802015-01-27 Low-Molecular-Weight Heparin or Dual Antiplatelet Therapy Is More Effective Than Aspirin Alone in Preventing Early Neurological Deterioration and Improving the 6-Month Outcome in Ischemic Stroke Patients Yi, Xingyang Chi, Wanzhang Wang, Chun Zhang, Biao Lin, Jing J Clin Neurol Original Article BACKGROUND AND PURPOSE: Dual antiplatelet therapy (DAT) with clopidogrel and aspirin has been shown to confer greater protection against early neurological deterioration (END) and early recurrent ischemic stroke (ERIS) than aspirin alone in patients who have experienced an acute ischemic stroke. However, few studies have compared the effects of anticoagulation therapy with low-molecular-weight heparin (LMWH), DAT, and aspirin. METHODS: Patients with acute ischemic stroke (n=1,467) were randomized to therapy groups receiving aspirin (200 mg daily for 14 days, followed by 100 mg daily for 6 months), DAT (200 mg of aspirin and 75 mg of clopidogrel daily for 14 days, then 100 mg of aspirin daily for 6 months), or LMWH (4,000 antifactor Xa IU of enoxaparin in 0.4 mL subcutaneously twice daily for 14 days, followed by 100 mg of aspirin daily for 6 months). The effects of these treatment strategies on the incidence of END, ERIS, and deep-vein thrombosis (DVT) were observed for 10-14 days after treatment, and their impacts on a good outcome were evaluated at 6 months. RESULTS: The DAT and LMWH were associated with a more significant reduction of END and ERIS within 14 days compared with aspirin-alone therapy. In addition, LMWH was associated with a significantly lower incidence of DVT within 14 days. At 6 months, DAT or LMWH improved the outcome among patients aged >70 years and those with symptomatic stenosis in the posterior circulation or basilar artery compared with aspirin. CONCLUSIONS: LMWH or DAT may be more effective than aspirin alone for reducing the incidence of END and ERIS within 14 days, and is associated with improved outcomes in elderly patients and those with stenosis in the posterior circulation or basilar artery at 6 months poststroke. Korean Neurological Association 2015-01 2015-01-02 /pmc/articles/PMC4302180/ /pubmed/25628738 http://dx.doi.org/10.3988/jcn.2015.11.1.57 Text en Copyright © 2015 Korean Neurological Association http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Yi, Xingyang
Chi, Wanzhang
Wang, Chun
Zhang, Biao
Lin, Jing
Low-Molecular-Weight Heparin or Dual Antiplatelet Therapy Is More Effective Than Aspirin Alone in Preventing Early Neurological Deterioration and Improving the 6-Month Outcome in Ischemic Stroke Patients
title Low-Molecular-Weight Heparin or Dual Antiplatelet Therapy Is More Effective Than Aspirin Alone in Preventing Early Neurological Deterioration and Improving the 6-Month Outcome in Ischemic Stroke Patients
title_full Low-Molecular-Weight Heparin or Dual Antiplatelet Therapy Is More Effective Than Aspirin Alone in Preventing Early Neurological Deterioration and Improving the 6-Month Outcome in Ischemic Stroke Patients
title_fullStr Low-Molecular-Weight Heparin or Dual Antiplatelet Therapy Is More Effective Than Aspirin Alone in Preventing Early Neurological Deterioration and Improving the 6-Month Outcome in Ischemic Stroke Patients
title_full_unstemmed Low-Molecular-Weight Heparin or Dual Antiplatelet Therapy Is More Effective Than Aspirin Alone in Preventing Early Neurological Deterioration and Improving the 6-Month Outcome in Ischemic Stroke Patients
title_short Low-Molecular-Weight Heparin or Dual Antiplatelet Therapy Is More Effective Than Aspirin Alone in Preventing Early Neurological Deterioration and Improving the 6-Month Outcome in Ischemic Stroke Patients
title_sort low-molecular-weight heparin or dual antiplatelet therapy is more effective than aspirin alone in preventing early neurological deterioration and improving the 6-month outcome in ischemic stroke patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302180/
https://www.ncbi.nlm.nih.gov/pubmed/25628738
http://dx.doi.org/10.3988/jcn.2015.11.1.57
work_keys_str_mv AT yixingyang lowmolecularweightheparinordualantiplatelettherapyismoreeffectivethanaspirinaloneinpreventingearlyneurologicaldeteriorationandimprovingthe6monthoutcomeinischemicstrokepatients
AT chiwanzhang lowmolecularweightheparinordualantiplatelettherapyismoreeffectivethanaspirinaloneinpreventingearlyneurologicaldeteriorationandimprovingthe6monthoutcomeinischemicstrokepatients
AT wangchun lowmolecularweightheparinordualantiplatelettherapyismoreeffectivethanaspirinaloneinpreventingearlyneurologicaldeteriorationandimprovingthe6monthoutcomeinischemicstrokepatients
AT zhangbiao lowmolecularweightheparinordualantiplatelettherapyismoreeffectivethanaspirinaloneinpreventingearlyneurologicaldeteriorationandimprovingthe6monthoutcomeinischemicstrokepatients
AT linjing lowmolecularweightheparinordualantiplatelettherapyismoreeffectivethanaspirinaloneinpreventingearlyneurologicaldeteriorationandimprovingthe6monthoutcomeinischemicstrokepatients